Long-Term Outcome of Hyper-CVAD-R for Burkitt Leukemia/Lymphoma and High-Grade B Cell Lymphoma: Focus on CNS Relapse

Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.
[Blood Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Hematopoietic Stem Cell Transplantation for Infants with High-Risk KMT2A Gene–Rearranged Acute Lymphoblastic Leukemia

43 patients received hematopoietic stem cell transplantation (HSCT) in first remission including 38 patients receiving protocol-specified HSCT with conditioning consisting of individualized targeted doses of busulfan, etoposide, and cyclophosphamide. Three-year event-free survival of 56.8% and overall survival of 80.2% were accomplished.
[Blood Advances]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Allogeneic Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: Results from the MANTLE-FIRST Study on Behalf of Fondazione Italiana Linfomi

Investigators retrospectively analyzed 55 patients who underwent allogeneic stem cell transplantation for mantle cell lymphoma relapsed or refractory after rituximab and high-dose cytarabine within the MANTLE-FIRST project.
[Leukemia & Lymphoma]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Single-Cell Profiling Reveals the Importance of CXCL13/CXCR5 Axis Biology in Lymphocyte-Rich Classic Hodgkin Lymphoma

Researchers examined the immune cell profile of eight cell suspension samples of Lymphocyte-rich classic Hodgkin lymphoma (LR-CHL) in comparison to 20 samples of the mixed cellularity and nodular sclerosis subtypes of CHL.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

Sutro Biopharma, Inc and BioNova Pharmaceuticals Limited announced an option agreement for BioNova to develop and commercialize STRO-001, a CD74-targeting Antibody-Drug Conjugate, for patients with hematologic cancers, in Greater China, including mainland China, Hong Kong, Macau and Taiwan.
[Sutro Biopharma, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

CAR-T Cell Therapy in T Cell Malignancies: Is Success a Low-Hanging Fruit?

Investigators highlight the preclinical and clinical efforts made for addressing the drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T cell malignancies.
[Stem Cell Research & Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

The Landscape of Tumor Cell States and Ecosystems in Diffuse Large B Cell Lymphoma

Researchers implemented EcoTyper, a machine-learning framework integrating transcriptome deconvolution and single-cell RNA sequencing, to characterize clinically relevant diffuse large B cell lymphoma cell states and ecosystems.
[Cancer Cell]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Autologous Transplant versus Chimeric Antigen Receptor T-Cell Therapy for Relapsed DLBCL in Partial Remission

Researchers identified adult diffuse large B-cell lymphoma (DLBCL) patients who received either an auto-hematopoietic cell transplant or CAR-T treatment with axicabtagene ciloleucelwhile in a partial remission by CT or PET scan.
[Blood]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies

The authors recruited 114 patients with B cell malignancies, comprising 77 acute lymphoblastic leukemia and 37 non-Hodgkin lymphoma patients, who were treated with CART19 cells.
[Journal of the National Cancer Institute]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Reverted Exhaustion Phenotype of Circulating Lymphocytes as Immune Correlate of Anti-PD1 First-Line Treatment in Hodgkin Lymphoma

Hodgkin lymphoma patients showed a decreased CD4 T-cell fraction, a higher percentage of effector-memory T cells and higher expression of activation markers at baseline.
[Leukemia]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

US FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma

BeiGene, Ltd. announced that BRUKINSA® (zanubrutinib) has received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen.
[BeiGene, Ltd.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share